Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 2Gastrointestinal 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 2Sarcoma 1Rhabdomyosarcoma 1Neoplasms 1Medulloblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Interventional × LY2940680 × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT01226485 2019-09-13

A Study in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
84 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01919398 2019-09-11

A Study of LY2940680 in Japanese Participants With Advanced Cancers

Eli Lilly and Company

Phase 1 Completed
19 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01697514 2013-08-27

A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma

Eli Lilly and Company

Phase 1 Withdrawn
CNSSarcoma

Medulloblastoma, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡